

Special Issue

Molecular Genetics, Signaling Pathways, and Therapeutic Strategies for Liver Cancer

Message from the Guest Editors

Liver cancer is a leading fatal human cancer. It is known to have a high degree of heterogeneity, leading to frequent treatment resistance and disease recurrence. There are a limited number of treatment options and they are not adequately effective. The hepatocarcinogenesis process of liver cancer is complex and involves the endeavor of malignant and immune components. There is an accumulation of various genetic and epigenetic alterations that pinpoint key signaling pathways or biological processes. With the emergence of different sequencing-based strategies, high-throughput screening platforms as well as computational algorithms, we can delineate the underlying molecular and cellular landscapes in liver cancer to a better extent. This Special Collection will focus on various niche areas that cover the basic as well as translational aspects of liver cancer research.

Guest Editors

Dr. Wai-Hung Ho Daniel

Department of Pathology and State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong SAR, China

Dr. Yuman Tsui

1. Department of Pathology, The University of Hong Kong, Pokfulam, Hong Kong
2. State Key Laboratory of Liver Research, The University of Hong Kong, Pokfulam, Hong Kong

Deadline for manuscript submissions

closed (31 October 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/175258

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)